A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
The negotiations list is here; Amgen, Horizon clear FTC hurdle; Fall biotech IPOs?; Novo buys biotech partner in obesity; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit